mTOR and cancer: Reason for dancing at the crossroads?

Current Opinion in Genetics and Development

Volumn 16, Issue 1, 2006, Pages 78-84

  Thomas, George V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; AP 23573; EVEROLIMUS; HAMARTIN; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TEMSIROLIMUS; TUBERIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; DANCING; DOSE RESPONSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; RASH; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; TUMOR SUPPRESSOR GENE;

ANIMALS; CLINICAL TRIALS; HUMANS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TUMOR MARKERS, BIOLOGICAL;

MAMMALIA;

EID: 30644468118     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2005.12.003     Document Type: Review

References (51)

1. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 2002 489 501
2. Y. Zhang, X. Gao, L.J. Saucedo, B. Ru, B.A. Edgar, and D. Pan Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins Nat Cell Biol 5 2003 578 581
3. K. Inoki, Y. Li, T. Zhu, J. Wu, and K.L. Guan TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat Cell Biol 4 2002 648 657
4. K. Inoki, T. Zhu, and K.L. Guan TSC2 mediates cellular energy response to control cell growth and survival Cell 115 2003 577 590
5. M.N. Corradetti, K. Inoki, N. Bardeesy, R.A. DePinho, and K.L. Guan Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome Genes Dev 18 2004 1533 1538
6. R.J. Shaw, N. Bardeesy, B.D. Manning, L. Lopez, M. Kosmatka, R.A. DePinho, and L.C. Cantley The LKB1 tumor suppressor negatively regulates mTOR signaling Cancer Cell 6 2004 91 99
7. D.H. Kim, D.D. Sarbassov, S.M. Ali, J.E. King, R.R. Latek, H. Erdjument-Bromage, P. Tempst, and D.M. Sabatini mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 2002 163 175
8. T. Schmelzle, and M.N. Hall TOR, a central controller of cell growth Cell 103 2000 253 262
9. M.A. Bjornsti, and P.J. Houghton The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 2004 335 348
10. C.L. Sawyers Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4 2003 343 348
11. H. Tang, E. Hornstein, M. Stolovich, G. Levy, M. Livingstone, D. Templeton, J. Avruch, and O. Meyuhas Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation Mol Cell Biol 21 2001 8671 8683
12. -/-mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway Mol Cell Biol 24 2004 3112 3124
13. E.C. Holland, N. Sonenberg, P.P. Pandolfi, and G. Thomas Signaling control of mRNA translation in cancer pathogenesis Oncogene 23 2004 3138 3144
14. ••].
15. ••] describe how eIF-4E, a mTOR effector, mediates anti-apoptotic drug resistance. The findings have important implications for rational combinatorial therapies.
16. G.J. Browne, and C.G. Proud Regulation of peptide-chain elongation in mammalian cells Eur J Biochem 269 2002 5360 5368
17. 1/2 (short half-lives), such as p21, and has implications for mTOR regulation for other such proteins.
18. K. Hara, Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch, and K. Yonezawa Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action Cell 110 2002 177 189
19. S.S. Schalm, D.C. Fingar, D.M. Sabatini, and J. Blenis TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function Curr Biol 13 2003 797 806
20. D.D. Sarbassov, S.M. Ali, D.H. Kim, D.A. Guertin, R.R. Latek, H. Erdjument-Bromage, P. Tempst, and D.M. Sabatini Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 14 2004 1296 1302 The authors describe Rictor, a new mTOR-GßL-interacting protein, which, in contrast to Raptor, neither regulates S6K1 nor binds FKBP12-rapamycin. Instead, the Rictor-mTOR complex modulates the PKCα phosphorylation and cytoskeletal modeling.
21. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101 In this study, the same authors go on to describe how the Rictor-mTOR complex is able to phosphorylate AKT on position Ser473 in vitro. Given that full Rictor-mTOR activity requires growth factors, this finding strengthens the suspicion that mTOR, when bound to Rictor, is a Ser473 kinase.
22. B.D. Manning, M.N. Logsdon, A.I. Lipovsky, D. Abbott, D.J. Kwiatkowski, and L.C. Cantley Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2 Genes Dev 19 2005 1773 1778 This study shows that S6K1 phosphorylates and inhibits the insulin-receptor substrate IRS1, an important mediator of insulin-receptor-dependent activation of PI3K. This feedback inhibition of AKT-mediated transformation might explain the benign nature of lesions found in the tuberous sclerosis syndrome.
23. O.J. Shah, Z. Wang, and T. Hunter Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies Curr Biol 14 2004 1650 1656
24. L. Rui, T.L. Fisher, J. Thomas, and M.F. White Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2 J Biol Chem 276 2001 40362 40367
25. E.K. Rowinsky Targeting the molecular target of rapamycin (mTOR) Curr Opin Oncol 16 2004 564 575 This review gives an excellent overview of the track record of mTOR inhibitors in clinical trials to date.
26. +/- mice Proc Natl Acad Sci USA 98 2001 10320 10325
27. M.S. Neshat, I.K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J.J. Gibbons, H. Wu, and C.L. Sawyers Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci USA 98 2001 10314 10319
28. K. Yu, L. Toral-Barza, C. Discafani, W.G. Zhang, J. Skotnicki, P. Frost, and J.J. Gibbons mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr Relat Cancer 8 2001 249 258
29. C.L. Sawyers Opportunities and challenges in the development of kinase inhibitor therapy for cancer Genes Dev 17 2003 2998 3010
30. M.B. Atkins, M. Hidalgo, W.M. Stadler, T.F. Logan, J.P. Dutcher, G.R. Hudes, Y. Park, S.H. Liou, B. Marshall, and J.P. Boni Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 2004 909 918
31. ••].
32. ••] uncover the mechanisms of sensitivity to EGFR inhibitors in subsets of lung cancer.
33. P.K. Majumder, P.G. Febbo, R. Bikoff, R. Berger, Q. Xue, L.M. McMahon, J. Manola, J. Brugarolas, T.J. McDonnell, and T.R. Golub mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways Nat Med 10 2004 594 601 Using preclinical information that either PTEN loss or AKT overexpression sensitizes xenograft tumors to mTOR inhibitors, these authors showed that treatment with RAD001was able to reverse the mPIN phenotype in their AKT transgenic mice. They go on to identify a biological readout of RAD001 activity (i.e. the HIF-regulated family of target genes).
34. C.C. Hudson, M. Liu, G.G. Chiang, D.M. Otterness, D.C. Loomis, F. Kaper, A.J. Giaccia, and R.T. Abraham Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin Mol Cell Biol 22 2002 7004 7014
35. G.L. Semenza Targeting HIF-1 for cancer therapy Nat Rev Cancer 3 2003 721 732
36. B.H. Jiang, J.Z. Zheng, M. Aoki, and P.K. Vogt Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells Proc Natl Acad Sci USA 97 2000 1749 1753
37. B.H. Jiang, G. Jiang, J.Z. Zheng, Z. Lu, T. Hunter, and P.K. Vogt Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1 Cell Growth Differ 12 2001 363 369
38. W. Zundel, C. Schindler, D. Haas-Kogan, A. Koong, F. Kaper, E. Chen, A.R. Gottschalk, H.E. Ryan, R.S. Johnson, and A.B. Jefferson Loss of PTEN facilitates HIF-1-mediated gene expression Genes Dev 14 2000 391 396
39. E. Laughner, P. Taghavi, K. Chiles, P.C. Mahon, and G.L. Semenza HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression Mol Cell Biol 21 2001 3995 4004
40. J.B. Brugarolas, F. Vazquez, A. Reddy, W.R. Sellers, and W.G. Kaelin Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways Cancer Cell 4 2003 147 158
41. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, S.M. Steinberg, H.X. Chen, and S.A. Rosenberg A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
42. G. Stallone, A. Schena, B. Infante, S. Di Paolo, A. Loverre, G. Maggio, E. Ranieri, L. Gesualdo, F.P. Schena, and G. Grandaliano Sirolimus for Kapos's sarcoma in renal-transplant recipients N Engl J Med 352 2005 1317 1323
43. R.A. Gatenby, and R.J. Gillies Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4 2004 891 899
44. S.M. Chang, J. Kuhn, P. Wen, H. Greenberg, D. Schiff, C. Conrad, K. Fink, H.I. Robins, T. Cloughesy, and L. De Angelis Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs Invest New Drugs 22 2004 427 435
45. S.M. Chang, P. Wen, T. Cloughesy, H. Greenberg, D. Schiff, C. Conrad, K. Fink, H.I. Robins, L. De Angelis, and J. Raizer Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme Invest New Drugs 23 2005 357 361
46. E. Galanis, J.C. Buckner, M.J. Maurer, J.I. Kreisberg, K. Ballman, J. Boni, J.M. Peralba, R.B. Jenkins, S.R. Dakhil, and R.F. Morton Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study J Clin Oncol 23 2005 5294 5304
47. T.E. Witzig, S.M. Geyer, I. Ghobrial, D.J. Inwards, R. Fonseca, P. Kurtin, S.M. Ansell, R. Luyun, P.J. Flynn, and R.F. Morton Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma J Clin Oncol 23 2005 5347 5356
48. I.B. Weinstein Cancer. Addiction to oncogenes - the Achilles heal of cancer Science 297 2002 63 64
49. G. Choe, S. Horvath, T.F. Cloughesy, K. Crosby, D. Seligson, A. Palotie, L. Inge, B.L. Smith, C.L. Sawyers, and P.S. Mischel Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo Cancer Res 63 2003 2742 2746
50. G.V. Thomas, S. Horvath, B.L. Smith, K. Crosby, L.A. Lebel, M. Schrage, J. Said, J. De Kernion, R.E. Reiter, and C.L. Sawyers Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer Clin Cancer Res 10 2004 8351 8356 This study and that by Choe et al. [49] describe a molecular signature for the PI3K-AKT pathway activation that can be probed in clinical samples and, thus, serve as a biomarker for patient selection and target inhibition.
51. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyer CL: Hypoxia-inducible factor determines sensitivity to mTOR inhibitors in kidney cancer. Nat Med 2006, in press.